Abstract
Background: The percentage of affected body surface area (BSA) can be used to monitor psoriasis disease activity, with a, BSA of 3%-10% indicating a moderate disease state and >10% indicating a severe disease state. The fully human anti–interleukin-17 receptor A monoclonal antibody brodalumab is efficacious for the treatment of adults with moderate to severe plaque psoriasis. This post hoc analysis evaluates change in, BSA involvement over 52 weeks of treatment with brodalumab in a randomized phase 3 trial (AMAGINE-1).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
